In our last post we explored the variation in prescribing rates between the UK regions. But what are the implications for your product at a key account level?
To understand this for a specific market, we examine the spend on diabetes patients at a primary care organisation (PCO) level. For this analysis we looked at how the 2015 community spend by clinical commissioning groups (CCG) on diabetes treatments and monitoring differed per registered patient with diabetes.
We found that the average CCG in England spent £339 per patient registered with diabetes in 2015. However this varied +/- 25% between the highest and lowest spending CCGs as shown below:
So how do the CCGs spending more per patient differ from those spending less per patient with diabetes? We examined the different drug types prescribed in each collective group of CCGs and the results are shown below:
CCGs spending more per patient with diabetes are shown on the left and those spending below the average spend in England are shown on the right. Above-average spending CCGs issued more prescriptions for “other antidiabetic drugs” than the below-average spending CCGs. Whilst the number of prescriptions for short, intermediate and long-acting insulins is similar in both groups, there are more prescriptions issued for biguanides and sulfonylureas in the lower-spend per diabetic patient CCGs.
So knowing that the high spend CCGs issue more prescriptions for certain drug groups is important but is this uniform across all their member practices or just the ones with a higher number of target patients?
We will investigate the differences in practice uptake of newer products in a future blog but for more details on the diabetes analysis sign up for our new diabetes market report at gprxdata.com/resources.